01—Abstract
Summary
Summary of the 8-K filed May 13, 2025. Cited figures are marked; the original filing is the authoritative source.
Exelixis, Inc. (Nasdaq: EXEL) reported first quarter 2025 financial results for the quarter ended April 4, 2025 (presented as March 31, 2025) and provided a corporate update, as furnished in Exhibit 99.1 press release dated May 13, 2025.
Total revenues were $555.4 milliona versus $425.2 million in the prior-year period, driven by net product revenues of $513.3 million (up from $378.5 million), which the company attributed to higher sales volume and higher average net selling price. Collaboration revenues declined to $42.2 million from $46.7 million. GAAP net income was $159.6 million, or $0.55 per diluted share, compared with $37.3 million, or $0.12 per diluted share, a year earlier.
Non-GAAP diluted EPS was $0.62b. Management raised full-year 2025 guidance for total revenues to $2.25 billion-$2.35 billion (from $2.15 billion-$2.25 billion) and for net product revenues to $2.05 billion-$2.15 billion (from $1.95 billion-$2.05 billion). The release highlights the March 2025 U.S. FDA approval of CABOMETYX for previously treated pancreatic and extra-pancreatic neuroendocrine tumors, which management described as the launch of CABOMETYX in advanced NET.
Management also outlined zanzalintinib pivotal readouts expected in the second half of 2025 from STELLAR-303 (colorectal cancer), STELLAR-304 (non-clear cell renal cell carcinoma), and a decision on moving into the phase 3 portion of STELLAR-305 (head and neck cancer), along with the planned STELLAR-311 pivotal study initiation in neuroendocrine tumors in the first half of 2025. The company discontinued development of the XL495 program based on early clinical data.
Capital return was active during the quarter: Exelixis had repurchased $494.5 millionc of common stock at an average price of $34.87 per share under programs authorized in August 2024 and February 2025, each with a December 31, 2025 deadline. Weighted-average diluted shares declined to 288.2 million as of March 31, 2025, from 326.3 million at the start of the first program in March 2023.
02—Key points
Key Highlights
- Total revenues of $555.4 million, up from $425.2 million; net product revenues of $513.3 million, up from $378.5 million, driven by higher volume and higher average net selling price.
- GAAP net income of $159.6 million, or $0.55 per diluted share, versus $0.12 per diluted share in the prior-year period; non-GAAP diluted EPS of $0.62.
- 2025 guidance raised: total revenues to $2.25-$2.35 billion and net product revenues to $2.05-$2.15 billion, each up $100 million from prior guidance.
- CABOMETYX received U.S. FDA approval in March 2025 for previously treated pancreatic and extra-pancreatic neuroendocrine tumors; management says the launch is underway.
- Zanzalintinib pivotal readouts expected in the second half of 2025 (STELLAR-303 in colorectal cancer, STELLAR-304 in non-clear cell renal cell carcinoma), plus a decision on STELLAR-305 phase 3 entry in head and neck cancer.
- Stock repurchases totaled $494.5 million at an average price of $34.87 per share as of March 31, 2025, under programs with a December 31, 2025 deadline; weighted-average diluted shares fell to 288.2 million.
- Collaboration revenues declined to $42.2 million from $46.7 million, mainly due to lower ex-U.S. cabozantinib royalties and lower development cost reimbursements.
03—Questions
Frequently Asked Questions
What drove the increase in revenue this quarter?
Net product revenues rose to $513.3 million from $378.5 million, which the company attributed to an increase in sales volume and an increase in average net selling price. Total revenues were $555.4 million compared with $425.2 million a year earlier.
Why did Exelixis raise its 2025 guidance?
Management said strong first-quarter CABOMETYX dynamics, including accelerating demand, new patient starts and revenues, supported raising full-year total revenues and net product revenues guidance by $100 million each. It also said it expects to provide further guidance updates as the NET launch builds momentum.
What are the key pipeline catalysts for the rest of 2025?
Management pointed to zanzalintinib pivotal readouts from STELLAR-303 (colorectal cancer) and STELLAR-304 (non-clear cell renal cell carcinoma) in the second half of 2025, a decision on moving STELLAR-305 (head and neck cancer) into phase 3, and the initiation of the STELLAR-311 pivotal study in neuroendocrine tumors in the first half of 2025.
How much has Exelixis returned to shareholders through buybacks?
As of March 31, 2025, Exelixis had repurchased $494.5 million of common stock at an average price of $34.87 per share under programs authorized in August 2024 and February 2025, each allowing repurchases before December 31, 2025. Weighted-average diluted shares outstanding fell to 288.2 million from 326.3 million since the first program was approved in March 2023.
Did the earnings improvement come from operations or other items?
Income from operations was $186.9 million versus $29.5 million a year earlier, and the prior-year period included $32.8 million of restructuring expense that did not recur. Net income also benefited from lower weighted-average share counts, which the company noted favorably affected per-share results; the provision for income taxes rose to $46.1 million from $12.0 million.
04—Continue